THE DE-ESCALATE STUDY: ATAZANAVIR OR ATAZANAVIR/RITONAVIR SUBSTITUTION IN HIV

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, controlled, pilot study to compare the safety and efficacy of substitution of Atazanavir (ATV) or ATV/Ritonavir (RTV) for Ritonavir boosted protein inhibitor (PI) in patients with ongoing viremia who are experiencing hyperlipidemia and/or requiring treatment with lipid lowering agents. In this study, 60 subjects on a Ritonavir-boosted PI-containing antiretroviral regimen who are experiencing hyperlipidemia and ongoing HIV viremia will be randomized in a 1:1:1 ratio to either switch the Ritonavir-boosted PI component of the antiretroviral regimen to ATV or ATV/RTV, or continue the Ritonavir-boosted PI-based regimen.